第202期 - 2026年11月6日
Brian SkorneyPaul MatteisYaron WerberAdam Feuerstein
- 民主党横扫是否会改善生物科技行业的基本面,还是加剧短期定价风险,嘉宾意见分裂。 XBI本周下跌3%,标普500指数约跌2.5%;Matteis认为,特朗普与民主党可能联手压低药价,带来“更大的下行风险”。Skorney认为医保可及性和投资有望净受益,Feuerstein预计立法将陷入停滞,Werber则认为利率和大盘疲弱的影响可能超过医疗立法。
- Vertex预期中的IgAN获批之后,真正难打的是商业竞争,而非监管审批。 11月30日的PDUFA日期让治疗中断数据未披露、是否需要监测IgG等问题浮出水面,但嘉宾普遍不认为Vertex会拿到格外严格的标签。Skorney强调,更大的劣势在于竞争对手已有肾功能结局数据,而Vertex可能还要用蛋白尿数据卖上约2年——“肾脏结局和生物标志物差别很大”。
- Revolution Medicines首个季度报出的1.98亿美元销售额超预期,但估值之争并未因此落幕。 胰腺癌药上市前5周销售额远超买方8000万至1亿美元的低预期,获益于扩大用药计划患者和积压需求。看空逻辑在于标签扩展前销售可能见顶,而当前估值意味着“执行必须完美”。
- Vykat XR和Madrigal的争议都围绕因果关系展开,但安全性隐忧背后的证据并不相同。 Feuerstein称,Vykat XR处方患者中有8人死亡、100多人住院;Prader–Willi综合征本身的并发症与已知药物风险存在重叠。Madrigal面临尚未证实的举报人指控,公司则援引约5.6万名接受治疗患者的情况,称未见明显肝毒性信号。嘉宾强调,药物上市后要“证明不存在”尤其困难。
- 一份据报提交的非营利机构裸盖菇素药物申报,可能在COMP360上市前就冲击Compass的定价。 Matteis质疑,竞争对手尚未公布III期结果、披露证据也更少,怎么已经提交NDA。低价替代品可能招致支付方施压,但REMS、专科渠道和监督治疗也可能维持不同市场:“这些诊所得能赚到钱。”
- Zolgensma肿瘤病例报道,让Matteis对AAV用于重症罕见病以外领域的谨慎态度更坚定。 有几例病例报告显示载体整合,使理论上的致癌风险更具体;不过,他仍认为该疗法对重症SMA的获益风险比有利。他更广泛的警告是:“在别处开发,风险自负”;Werber则以Ultragenyx新获批的罕见病疗法作为补充。
- Pelacarsen试验失败,对Lp(a)疗法在其他心血管风险已得到控制的患者中的逻辑提出挑战。 Werber期待次日上午AHA的报告揭示亚组是否仍有获益,或开发方向是否应转向一级预防。Amgen可能调整研究设计,但影响仍“完全有待观察”。
- 下一批管线催化剂,考验的不只是初始疗效,也包括症状改善、持久性和安全性。 Werber对Amgen年末的干燥综合征症状性疾病读数“相当乐观”。由于需要增加持久性随访,BeOne的BTK降解剂申报时间看起来更可能落在明年年中左右;公司称这与安全性无关。CAR-T方面,Gilead的PDUFA日期临近12月23日,Legend则报告称,类固醇预防用药将帕金森症状风险从约4–6%降至1.25%。
1. 大选带来药价与制度走向上的不同押注
- 在XBI本周下跌3%、标普500指数约跌2.5%的背景下,Skorney将选举结果形容为一场“蓝色浪潮”:参议院翻蓝7席,众议院翻蓝42席。他认为,选举的宏观影响主要落在财政政策、利率和资本成本上:利率变化会显著影响长周期生物科技公司的净现值(NPV),而现金流充沛的制药公司与研发阶段的公司受到的影响可能不同。Werber认为,宏观因素对行业的影响可能超过药价政策;AI监管和大盘走弱也可能波及生物科技。他的条件性看多逻辑是,与上一轮陡峭的加息周期相比,若利率上升放缓,生物科技可能更不受冲击。
- Skorney指出,新当选官员曾竞选承诺,撤销对ACA补贴、Medicaid、NIH、CDC和FDA经费的削减。Matteis将制度修复与股票表现区分开来:恢复HHS公信力、提升FDA监管一致性,长期可能有利;药价则是特朗普与民主党可能达成妥协的领域。MFN和关税讨论此前并未带来多少实际影响,而专科药上市价格却屡屡高于预期。他对短期的判断是“更大的下行风险”;Feuerstein则建议药企别再每获批一款药就试图创下价格纪录。
- Feuerstein对华盛顿的基准判断颇为悲观:新闻头条会很多,实事却不会有多少——“这就是华盛顿”。Skorney对净影响的判断不同。他说,许多在红州胜选的民主党人立场偏左,但选民是对特朗普政策不满的中右派选民;他认为,跨党派合作可以改善医疗可及性、带来新的投资,而不会给行业造成灾难性后果。不过,Medicare for All和激进药价提案仍会带来相当多的噪音。
- FDA继任人选仍未确定。Skorney肯定代理局长Kyle Diamantas,几位嘉宾则怀疑Heidi Overton能否获得确认。Matteis质疑即将离任的参议员是否会在剩余会期优先处理提名。争议减少让监管环境显得更稳定,但嘉宾认为,在看到更长时间的监管决策记录前,还不能断言监管一致性已经恢复;单个有争议的申请不足以证明这一点。
2. Vertex的IgAN争论,核心在于获批与长期竞争力是两回事
- Feuerstein介绍了Vertex候选药povetacicept,讨论中简称“POV”:PDUFA日期为11月30日,获批“几乎没有悬念”。一名匿名客户提交公民请愿书,要求监测免疫球蛋白;其依据是试验方案规定,当IgG低于某个阈值时应中断治疗。Vertex拒绝披露有多少患者中断治疗,并强调治疗组与对照组感染率相近。
- Skorney称,B细胞调节有望成为“奇迹疗法”。他提到,Otsuka的平均eGFR轨迹基本持平;他印象中,复合肾脏结局风险降低约98%,移植人数为0,而安慰剂组可能有5人。但具有保护作用的IgG也会下降。尤其是在发生过治疗中断的情况下,短期试验无法说明,在他所说的“20年的疾病”中,更深度的免疫抑制会带来怎样的感染后果。
- 关于标签,Skorney的观点是:“要么整个药物类别都这么做,要么就都不这么做。”Otsuka和Vera也在试验中监测免疫球蛋白,但标签并无相应要求。一位嘉宾直觉上认为不会增加监测要求,同时承认仍有不确定性。Skorney认为,Vertex管理层反复表示标签预计相近,这一判断颇有说服力;但他仍批评公司拒绝回答患者中断治疗的问题。
- 更大的商业难题是,Vertex可能以较少的随访数据成为第三家入场者。Skorney预计,在竞争对手转为全面获批的同时,Vertex还要约2年才能拿出肾功能结局数据;蛋白尿终究只是生物标志物。一位嘉宾提到,Vertex在疼痛领域和镰状细胞病药物Casgevy上的商业表现不佳,值得作为执行层面的警示。展望更远,Skorney看好Biohaven和Argenx选择性靶向Gd-IgA1的方案;按他的判断,这类方案可能避免耗竭具有保护作用的IgG。
3. Revolution首批销售数据迅速抬高预期,估值争论却仍在
- Feuerstein先提到买方对Revolution Medicines胰腺癌药上市前5周销售额的低预期:8000万至1亿美元。公司首次披露的销售额达到1.98亿美元,远超预期。嘉宾称这可能是一次出色的肿瘤药上市表现,但也指出,扩大用药计划患者和积压需求推高了首批销售,这些助力在第四季度不会以同样方式重现。
- Matteis提出看空一方的核心问题:销售额会不会在3个季度内走平,之后只能等待一线治疗或其他适应症扩展?他以Alumis和Insmed作历史对照:买方预测跑赢公开一致预期,直到“超预期已经不够”。他明确承认,Revolution仍可能成为“真正的巨无霸”。Werber对估值的判断则不留情面:股票越贵,“执行就必须完美”。
4. Vykat XR安全性报告重新点燃获益风险争论
- Feuerstein称,Soleno开发、现由Neurocrine销售的Vykat XR,处方患者中有8人死亡、远超100人住院。他取得了其中7例死亡的病例报告,并提到低血糖和水肿等情况。因果归属并不容易:Prader–Willi综合征本身就可能引发严重并发症,而水肿也是已知且列入药品标签的风险。
- Skorney强调,这款药的疗效并非传统意义上“大获全胜”:初次主要分析未成功后,药物依据一项随机撤药试验获批。这样的疗效结果,会让人更难接受潜在严重伤害。他还认为,Neurocrine股价受到的冲击已经超过其收购Soleno所支付的代价;投资层面更具体的问题,是这笔收购能否带来可观现金流。
- 一位嘉宾认为,Neurocrine首席医疗官“非常可信”,并将她的表态理解为:公司相信现有标签已充分描述风险,同时计划研究高风险患者。Feuerstein反驳说,这听起来像是“两头都说”。他怀疑这项研究能否识别出不适合接受治疗的患者,就像杜氏肌营养不良治疗决策中需要区分可行走与不可行走患者一样。
5. Madrigal诉讼指称存在信号,但医生并未报告类似情况
- Feuerstein介绍,一名前Madrigal高管提起举报人诉讼,指控管理层压下了对试验和上市后监测中肝损伤问题的调查。原告称,自己提出这些担忧后遭到降职并被迫辞职。这些仍是指控;Madrigal尚未正式回应诉状,并表示将积极抗辩。
- 一位嘉宾转述了公司的说法:药物已有相当大的患者暴露量——获批约4年,约5.6万名MASH患者接受过Rezdiffra治疗,尚未发现明显的药物性肝损伤问题。另一位嘉宾表示,经常与MASH医生交流的投资者并未听到与这些指控相似的毒性报告。这被认为颇具说服力,但诉讼指控是否成立仍未有定论。
- 一位嘉宾看不出这些指控如何明确导致已上市药物的情况发生实质变化。另一位解释了因果归属的难点:肝病进展本身会导致肝硬化、移植和病情恶化;没有对照组,常规肝损伤评估很难厘清原因。讨论认为,考虑到患者暴露量,肝毒性很可能性不大,但也强调,药物上市后要“证明不存在”并不容易。
6. 非营利机构申报为Compass的商业预期增添变数
- Matteis谈到一则令人意外的报道:Usona Institute已完成裸盖菇素药物的NDA申报。其III期试验约一年前完成,结果尚未公开,甚至是否在技术意义上取得成功也不清楚。Compass的COMP360针对难治性抑郁症,而非范围更广的重度抑郁症;该药正接近提交申请,持有一张FDA局长优先审评券,距离获批可能只剩几个月。
- 监管层面的疑问在于证据。Matteis原本以为这家非营利机构需要再做一项III期试验;他还说,Compass曾与研究者沟通,但对方并不知道试验结果。他也提到,CDER负责人此前曾在Usona工作。他明确表示,不清楚该官员是否回避了相关事项,也不知道这层关系是否对申报产生了影响。
- 商业层面上,非营利机构提供的低价裸盖菇素可能让支付方要求患者优先使用。但REMS、专科药房和有监督的诊所治疗都带来成本:“这些诊所得能赚到钱。”Matteis设想市场可能分成不同渠道,例如非营利机构通过VA提供治疗,Compass则服务于专科干预诊所。过去被视为迷幻药商业化障碍的运营复杂性,因此也可能保护Compass商业模式的一部分。
- 一位嘉宾质疑,监管药品价格不低、蘑菇却越来越容易获得,两者如何共存,并提到了大麻素和氯胺酮的先例。Matteis回应称,严重疾病患者看重成分可靠、专业给药和相互作用管理。他预计,即使娱乐性使用普遍存在,市场仍会青睐品牌药和受控治疗环境。另一位嘉宾认为,非营利机构的进展对LSD或5-MeO-DMT等不同作用机制的药物影响可能很小。
7. Zolgensma病例让基因疗法的适用边界更加清晰
- Matteis谈到Zolgensma上市后报告的少数肿瘤病例,其中有几例出现载体整合证据。他并未为所有媒体报道或家长说法背书,也没有说风险毫无变化;但对重症1/2型SMA患者,他仍认为该疗法的获益风险比有利,不过替代疗法也很重要。在鞘内给药、口服药竞争和一次性基因疗法并存的情况下,Spinraza仍有韧性;Matteis认为,这反映了医生和患者对它的信心,颇值得关注。
- 他更广泛的结论是,AAV目前“感觉更像是一种罕见病疗法”,尤其是在替代方案较好或疾病严重程度较低的情况下。他还提到其他基因疗法上市后的安全性问题,包括肝损伤和可能致死的事件。Werber则补充了未满足需求显著的例子:Ultragenyx新获批的GSD1a和MPS IIIA疗法,以及预计提交的OTC缺乏症药物申请。GSD1a患者为了预防危险的低血糖,一整天都要摄入玉米淀粉;MPS IIIA则会造成严重的神经发育恶化。
8. Amgen读数同时检验靶点机制与可用的差异化优势
- Werber预告,pelacarsen将在次日上午8:45于AHA公布数据。Ionis/Novartis的Lp(a)项目已经失败;对于LDL及其他风险因素控制良好的患者,结果看起来几乎没有显著获益。他希望看到亚组证据,包括疗效与基线LDL之间的关系,或能否找到支持一级预防的线索。Amgen可能调整正在进行的研究,但具体怎么调整“完全有待观察”。
- Werber预计,Amgen的dazodalibep数据将于次周三上午8:45在ACR公布。他认为,系统性疾病数据“好得多”,优于Novartis的ianalumab;后者需要合并两项III期试验才能达到统计学显著性。24周数据达到主要和次要终点;12周数据达到主要终点,他认为症状指标也只是呈现趋势。他对年末公布的症状性疾病研究“相当乐观”,该研究针对约2/3至75%的患者。
- Amgen还交出业绩超预期并上调指引的表现,MariTide研究入组速度很快。Werber预计,笔型制剂数据将在明年6月前公布;若结果成功,他认为公司可能在明年下半年提交申请。针对其他GLP-1疗法的换药研究也已启动,为最初疗效讨论之外再添一条开发路径。
9. 肿瘤管线把持久性与安全性摆在缓解率旁边
- Werber提到,BeOne再次上调业绩指引,Brukinsa表现强劲,其首创BTK降解剂也公布了积极的II期结果。由于增加了持久性随访,且公司明确表示“与安全性无关”,Werber将申报时间预期调整至明年年中左右。他推测,FDA希望看到所有患者及各亚组达到最低随访时长,尤其是此前接受过Lilly的Jaypirca治疗、入组时间较晚的患者;这仍是他的解读。
- BeOne针对Jaypirca的III期头对头研究正在推进,Werber也认同管理层有信心证明疗效优越。另一方面,BeOne重申,其PRMT5候选药与Revolution的药物之间预计不会发生药物相互作用。Werber认为,正是Tango遇到的相互作用问题,促使Revolution选择与BeOne正式合作。
- Gilead的CAR-T候选药anito-cel的PDUFA日期为12月23日。Werber预计,它的疗效略低于Legend的产品,但安全性会明显更好;ASH摘要没有披露多少新的疗效信息,因此会议上的更新值得关注。与此同时,Legend报告称,类固醇预防用药将帕金森症状风险从约4–6%降至1.25%,但风险仍未完全消除。
- Legend早期体内CAR-T淋巴瘤数据更新也引起Werber关注:缓解率接近100%,持久性数据延长至5个月,目前安全性相当干净。他认为,早期缓解表现优于现有体外CAR-T产品。Werber明确强调,这只是一个令人鼓舞的早期信号,仍需更长时间观察。
完整逐字稿
本集逐字稿暂无译文,当前显示原文。
You are listening to Biotech Hangout, a live and unedited weekly discussion of all the latest news in our industry with a group of biotech leaders and experts and, for some inexplicable reason, me, Brian Skorney. With me today are co-hosts Paul Matteis, Yaron Werber, and, as a special guest co-host, Adam Feuerstein. For more information about our hosts and guest speakers or to listen to the most recent episode, please go to biotech hangouts.com.
So everyone, this has been a pretty busy week. XBI is down 3% on the week right now. The S&P is down around 2.5%. It’s the heaviest earnings week of the quarter, at least for me, and we did have a little election here in the U.S. I’m not sure whose idea it was to give me the reins to run point on Hangout today and bring Adam in at some point. I’m hopeful we’re not going to get canceled, but either way, I think we’re going to have a really fun discussion today.
1. The Election’s Biotech Impact
Let’s start with something none of us are really fit to opine on, but we’re going to do it anyway: policy. Blue tsunami on Tuesday night. I’m not sure if everyone had heard about this news this week, but the midterm elections led to a pretty big shift in legislative control. Democrats took both the House and Senate, and not by small margins. Polling in recent years has tended to underestimate Republicans, so while there was definitely an overall view that the Democrats were going to take the House and maybe squeeze out a Senate majority, this time polling and even the betting odds seemed to massively underestimate them.
The party wound up flipping 7 seats in the Senate and 42 in the House. The last I checked, 2 Senate races and 29 House races were still uncalled. Some of those flips were pretty surprising. One that could have a big impact on health care and our sector is South Carolina, where Annie Andrews unseated Darlene Graham. I want to talk about Dr. Andrews a little later, too. Texas and Kansas both had Senate seat flips, and Texas even elected a Democratic governor.
There are pretty meaningful implications for a bunch of things relevant to us. We’ve all learned recently that government policy can have a big impact on the macro, which winds up affecting us to a great degree—maybe more than we thought when we started in biotech. There are questions about how the new government might affect fiscal policy, growth, and inflation. Monetary policy has been under more and more government pressure in recent years. Interest rates, both in terms of Fed funds rates and real interest rates, all have major effects on the cost of capital, leading to big shifts in broad-based investing.
Because biotech has such a long investment cycle, there’s a huge impact on NPV from those changes. And because pharma companies can be such cash cows, there may be an inverse effect relative to development-stage biotech.
There’s also going to be a lot of health care-specific policy on the table. The One Big Beautiful Bill enacted numerous changes to cut ACA subsidies and Medicaid. We’ve talked extensively here about the cuts to NIH, CDC, and FDA. There’s ample evidence that many of these newly elected officials have been campaigning to reverse those things.
One of the many interesting things is that a lot of these newly elected legislators are medical doctors: 2 senators and 4 congressmen. Abdul El-Sayed was perhaps part of the most visible Senate election nationally. He got his MD from Columbia, just north of me here in Washington Heights, then a doctorate in public health. He was a professor of epidemiology at Columbia and has had several health administration roles in Michigan.
He’s been an outspoken advocate for Medicare for All, which I think a lot of us in biotech probably don’t love. He’s written about lowering prescription drug costs, which I definitely don’t think a lot of us in biotech love. And he’s been a sharp critic of HHS Secretary RFK Jr., which I think a lot of us in biotech probably do love.
The other MD elected to the Senate is Annie Andrews, who turned a pretty red seat blue. She’s a pediatrician who has practiced since 2009, and health care has been a big part of her platform. She’s outspoken about fully funding Medicaid again, protecting Medicare, and fully funding CDC and NIH. She explicitly condemned RFK Jr. and said, “He’s been my professional arch nemesis for decades, and any other pediatrician in this country would say the same.”
I don’t know about any other pediatrician, but I can attest to being married to one. Pretty much every pediatrician I know feels that way.
The normal gut reaction from both capital markets and pharma is that Democrats are bad for both. We saw volatility all over the map as the election was going on Tuesday night, showing the magnitude of the sweep. Futures were significantly down, but by Wednesday’s open they had reversed, and the market had a big move up. The Dow saw its best performance on a post-midterm-election day in 44 years.
There were even some cracks then, particularly around names with exposure to the data center buildout, another area that a lot of these candidates’ platforms were pushing against. What we saw on Thursday gave it all back and then some. I think we can all attest that it was a really horrific day yesterday.
With all that being said, we’re now brought to the Biotech Hangout brain trust. I’d love to go around the horn and hear everyone’s top reasons to be bullish on biotech with this new government, their top reasons to be bearish, and how they think it nets out. I’ve already spoken a lot, and I need to hear what all the smarter people in the group have to say so I can take the best takeaways for myself.
I’ll round it out with an opinion, but I’d love to hear from my other co-hosts. What are you guys hearing from investors? What are you telling investors about the outlook with this new government?
Should I go briefly?
Do it.
Thanks, Skorney. You should have a radio show, dude. That was awesome. Just sit and ramble. I love it. I would listen.
No, no, we’re going to nominate you to be the host every week from now on.
Yeah, that was great. I mean, for health care broadly, I couldn’t agree more with what you’re saying, Brian. Rescuing the credibility of HHS is important. We’ve obviously had some tough times with the FDA. It feels a little bit more stable, but we don’t have a long track record with the new leadership of the agency right now.
Some of the impacts of RFK on our sector are indirect or more specific, like things with vaccines. But having greater stability is important. I want the FDA to get back to a point where we look up to it for its standards and consistency, and it feels like it’s going to take changes on the political side to get us to a more stable place.
For drug stocks, it does feel like this introduces greater risk. The past couple of years have been marked by chatter around MFN and tariffs, with nothing of any consequence. I think a number of us—Skorney, Yaron, and I—cover companies in different specialty indications where they’ve priced way above expectations and launches have crushed it. I’d already been talking to investors who felt like some of the pricing felt a little unsustainable. It seems like if Trump decides to work with this Congress, drug pricing could be a logical area of compromise.
To me, that’s the biggest risk. Maybe the FDA stability issue is more of a longer-term thing, and maybe it’s a good thing for the sector and for society. I don’t know if it becomes more stable in the near term. I’m not sure if this new commissioner gets confirmed or how that all looks. For stocks, there’s probably more downside risk from this kind of stuff in the next year, even if there might be healthier improvements to major institutions over the long term. What does everyone else think? Adam, do you want to go next?
Oh, you want me to go? Gee. I don’t have a lot to say here other than that I agree with everything. I agree with much of what Brian and Paul said. If I put on my cynical hat, I’d say nothing changes. There’ll be a lot of rhetoric, particularly around drug pricing, but I don’t know. There seemed to be a big effort over the last 2 years, and it amounted to very little, so you sort of have to believe the Democrats can do something more effectively. I don’t know if that’s necessarily going to be true.
Paul, you do bring up a good point: if Trump decides he wants to work with the Democrats, maybe drug pricing is one of those things. But again, my cynical nature says this is D.C., and they’ll manage not to do a lot.
There’ll be a lot of headlines, but at the end of the day it won’t really matter.
Yeah, I tend to agree. I think we’re going to be pretty clearly in gridlock for the next 2 years. We’ll need to see exactly how much they try to go after Trump for whatever mishaps one can bring up and discuss, and whether that’s going to come back and bite them in the next election as it did last time is TBD.
The way I’m thinking about it is that the macro is almost more important for biotech than drug pricing. When we talk about macro, I’m talking about interest rates, what’s going to happen with AI regulation, and the view on tech holistically, because if the market’s going to be under pressure, it’s hard to see how biotech is immune. So I think it’s a question of how much collateral damage we’re going to see. If they’re really going to go after AI, whether through regulation or what happens with the data centers, I don’t know that biotech is going to be the beneficiary of the trade, especially if rates stay higher.
There’s a real question about whether biotech was impacted last time because of rates, because it was the delta—the slope of how much rates went up and how quickly—versus just higher for longer. It looks like rates are going to go higher and stay there for an unknown length of time. I think the bull case in biotech is that rates are going to go up with a slower slope now, so we’ll be more immune. So far, if you look at the indices, one of the challenges, as we all know, is that the XBI isn’t just biotech; it’s got some diagnostics in there. The IBB is different, but it definitely looks very different from the overall tech indices right now. So we’re sort of benefiting, but we’ll need to see. Anyway, I think it’s going to be more market-driven, in our view.
I do wonder, Yaron and Paul, about Heidi Overton at the FDA—what this means for her and whether that nomination happens or not.
Yeah. I kind of feel like no. She’s not all MAHA.
I kind of feel like no, too. If you put me on the spot and said I had to give you a prediction, I would say no.
You know what? I actually think I’m really happy with Kyle Diamantas. I was a little upset he wasn’t the actual nominee, and I understand maybe he doesn’t even really want the permanent job. Janet Woodcock was interim commissioner for a really long time. I forget, there’s some statutory rule about how long you can have an acting commissioner in place. But I’m happy. I think he’s done a really good job, certainly in contrast to his predecessor. I think the status quo at the FDA feels much more stable right now under him, so I’m happy to have it.
I mean, is it stable? I totally agree. I’m not playing devil’s advocate at all, but is it stable because there are just no longer major controversies every 5 minutes, and they’re not putting out policy papers every 2 weeks and then ignoring them?
Well, it’s definitely stable because the guy running the agency isn’t doing walk-and-talk videos or podcasts. From that perspective, it’s much more stable.
Not commenting on programs on CNBC and conflating 2 drugs. Ultimately, we’d have to see more regulatory actions play out over time to understand stability, to Yaron’s point. If Unicycive gets approved or rejected, it’s hard to say it’s any sort of referendum on FDA stability, because this current iteration of the FDA has been a saga across 2 or 3 different leadership teams. But I agree with Brian: the current commissioner seems good. It just sounds like he doesn’t want the job.
We talked to a consultant the other day, just as it relates to what the blue wave could mean. One speculation was—and no one knows—but if you’re an outgoing Republican senator, maybe you went down in this election and were a big supporter of the Trump agenda. Do you really want to confirm this commissioner? How high a priority is that? We’ll also see what’s happening with HHS leadership at the same time. I don’t know. In the backdrop of that, how long is the Senate in session between now and January 20th? Is this even a top priority? I have to wonder if the FDA commissioner situation could drag on with uncertainty for some time.
Well, yeah. I guess I’ll wrap things up. We’ve talked a lot, and I want to get into more of the specific stuff, but I think we’re going to hear a lot of noise. We have some loud DSA voices in the Democratic Party, and you’re probably going to hear about Medicare for All. You’re probably going to hear Bernie Sanders pushing to escalate talks of drastically reducing drug prices.
But when I look at what happened, most of these newly elected Democrats in red states are really left of center, right? They got elected by people who are right of center, willing to flip and frustrated with Trump policy. So I’m more optimistic than Adam that things will get done and there’ll be some collaboration. Trump has hinted at it, but no one knows; Trump is very hard to predict. I think what we’ll see are things that aren’t catastrophically bad for the sector and maybe even modestly good. I think a lot of access and new investment will be freed up. So I think it’s a net positive, but we’re in for some noise over the next couple of months. I also agree with Yaron that the macro, interest rates, and spending outside of biotech can have a material impact.
The industry might do itself a favor by not trying to set record pricing for every drug that gets approved. Maybe throttle it back a little bit. That might be a good idea.
Maybe.
We’ve been having this conversation for 20 years, right? Keep doing this.
I know, but it just seems like it’s gotten worse. I don’t know.
No, and I didn’t mean to imply that it wasn’t people’s own doing. I think you’re right, Adam. It’s kind of crazy. I think let’s move on from some of the election stuff and get into more specific stuff. There are a lot of juicy things to talk about. It was a dense earnings week, but I don’t think we’re just going to recap earnings here. I think we’re going to have some fun debates on a few things that investors have been fighting about.
2. Vertex’s IgAN Label Debate
I’m not going to be the one to introduce this nuanced debate around Vertex’s soon-to-be-approved drug for IgAN, but I’m definitely opinionated on it. I’m looking forward to this discussion with the others, but I’m going to pass it over to our guest speaker today, Adam Feuerstein, to give us the setup.
Yeah. The setup on this, Brian, is Vertex’s IgA nephropathy drug, povetacicept. We’ll call it POV. The PDUFA date is November 30th, so it’s coming up. I think, as you alluded to in your intro, everyone thinks this is getting approved. There’s very little doubt that this drug is going to get approved. If and when it is approved, it will compete against the Otsuka drug and the Vera drug in IgAN. It’s a very large market. Those 2 drugs are already out there competing, and we’ll have Vertex’s POV coming in to compete.
What’s been kind of interesting over the last couple of weeks is this controversy over a treatment halt that was built into the protocol of Vertex’s phase 3 study. It was something no one knew about until a citizen petition was filed with the FDA. It was filed by a law firm on behalf of an anonymous client, asking the FDA to require monitoring of immunoglobulin levels in the POV label. Apparently, in the protocol, if IgG levels dropped below a certain threshold, there was a requirement that you could temporarily halt the use of POV until those IgG levels returned to normal. I guess we didn’t know about that until it came out in the citizen petition.
Naturally, people asked Vertex, “How many patients in your study had their treatment temporarily interrupted?” Vertex has not provided that answer; they’ve declined to provide it. What Vertex has said is that the most important thing here is infection risk, because if IgG levels go down, patients have a higher risk of infection. Yet if you look at their phase 3 study, the infection risk was the same in the drug arm and the control arm.
Therefore, there is no infection risk, and Vertex has stuck to that line. They have not provided more detail about whether any patients actually had to have their treatment temporarily halted. That matters because Otsuka’s and Vera’s drugs do not have patient-monitoring requirements in their labels. If that were introduced into the povetacicept label, it would put Vertex at a competitive disadvantage.
So, Brian, what do you think?
I love this debate. The first thing to be said is that this mechanism is showing miraculous data. We could get into the nuances of the mechanism, because there are slightly different hypotheses that may have applicability, but let’s just say that targeting B-cell modulation to lower immunoglobulins, including IgA, seems, for the most part, to stop the progression of the disease. Certainly, in the Otsuka data, which includes multiple years and hundreds of patients, it looks that way.
We don’t know all the patient-level data, but the mean eGFR decline in their Phase 3 study is basically zero. It’s actually up a little bit. At ASN last week, we also learned that they have a huge impact on outcomes. I think there was a 98% reduction in composite kidney outcomes. Zero patients on treatment went on to receive a kidney transplant, versus, I think, 5 on placebo.
You interfere with B cells and their ability to make IgA, and this is a miracle treatment for patients with IgA nephropathy. The downside is something we know about well beyond this data. There’s an approved BAFF inhibitor that does something very similar to these drugs, called belimumab. As long as you give this drug, IgG and all the other immunoglobulins go down. You’re basically impairing B-cell function, and B cells make immunoglobulins.
If you make no immunoglobulins, you run serious infectious risk. If you look at the belimumab data, in a different indication, lupus, there’s about a 1-in-10,000 risk of PML. As we all know from our days covering Biogen, that’s a very deadly reactivation of an infection called the JC virus.
There’s some level of inevitability that you will increase infections. Vertex’s argument is, “Yes, we see IgG reductions, as does Otsuka’s sibeprenlimab and Vera’s atacicept, as does anything that is going to suppress B-cell function. But look at the infections—there’s nothing that jumps out in the safety data.” I don’t think that’s a fair argument. It’s a short study. B cells—or IgGs—are declining throughout the entire study, and they’re not getting to a trough. IgA nephropathy is a 20-year disease; these patients are going to be on these drugs for 20 years.
Just because you’re not seeing an increase in infections when you’re reducing B cells or IgG by half of what you’re ultimately going to do, it doesn’t mean that when you get all the way down to zero, there won’t be an infection risk. I do think it’s a little bit of gaming the clinical trial to say, “Our IgG reductions aren’t that bad. We don’t have any cases of hypogammaglobulinemia,” when it’s because the study is designed to monitor IgGs heavily and interrupt treatment when they go below a certain level. Then they can say, “Our IgGs never went below this threshold level of hypogammaglobulinemia.” It’s an on-mechanism effect, so if you stop exposure to the mechanism, of course it’s going to happen.
These drugs are great. The benefit is more than worth the risk. It takes some thoughtfulness about monitoring, treatment holidays, and how to think about infection risk versus who you treat. Ultimately, I think there are better ways to do this. You guys are going to make fun of me for being a big Biohaven bull here, but this is a sort of single-immunoglobulin issue. It’s Gd-IgA1. If you can just target Gd-IgA1, you’re not going to have any of these infectious risks. No one’s going to have hypogammaglobulinemia, and no one’s going to see IgG reductions.
It’s not just Biohaven starting a pivotal study with its Gd-IgA1 reducer; argenx also has an IgA sweeper, and that data looks really good. I think we’re seeing more and more targeted, selective therapy. Vertex is going to be third to launch. They have much less data than Otsuka, which, for this group of mechanisms, I think is really the ideal drug.
Brian, what would you do with the label if you were the FDA on this monitoring issue? As an analyst covering this, I feel like it’s a little bit unknowable to guess how this plays out. My gut is that they’re not going to get the monitoring requirement, but I really don’t know.
I don’t think the FDA will require it. Again, Vertex is gaming the system a little bit here, but this is on-mechanism. It happens with sibeprenlimab and atacicept. We can see there’s monitoring when we look at the New England Journal articles, and we have the IgG data for everyone. So it is monitored, but they didn’t require monitoring on the label here.
I think it’s sort of: you do it for the class, or you don’t do it for the class. So far, the FDA has not done it for the class. There may arguably be a little more evidence that povetacicept could lower IgGs more. I think they had 3 cases of hypogammaglobulinemia in the Phase 1 study, but these are all small numbers and hard to compare.
I think the FDA only puts some sort of IgG-monitoring mechanism on the label if they’re going to do it for all of these B-cell modulators. The bigger issue is what nephrologists do. I don’t know what you guys are hearing from ASN, but nephrologists are aware of this. No one’s saying, “Oh, this lowers IgGs? I never knew that,” just because this protocol came out. They know this is going to take more attention in terms of managing these patients down the road.
You also have to account for the fact that Vertex has been asked about the label, both at the ASN meeting and on the earnings call. Reshma has been very clear that they feel they’re going to get essentially the same label as everyone else, without patient monitoring. I tend to believe that. It would be odd for them to be as aggressive as they’ve been if they didn’t know what was going on behind the scenes, even though they don’t want to answer that question that keeps getting asked.
The other thing, stepping back, is that what I find fascinating about all this is that this is going to be the first time since hepatitis C that Vertex has to compete in a market. They obviously don’t compete now with cystic fibrosis, and—
Well, I mean, yeah. If you want to say pain and—
Yeah, and how miserably have they done with pain? That’s been a total disaster from a commercial perspective, as has Casgevy in sickle cell. That’s a financial black hole they keep pouring money into.
And so, to me, that’s kind of interesting. Vertex has never really had to compete; they really know how to work for their supper, so to speak. Here they have 2 very formidable competitors with drugs that seem to help patients quite a bit. There’s not a lot of daylight between these 3 drugs. They’re coming in third to market, as you said, Brian, with less data because of the follow-up and everything. It’ll be very interesting to see how they compare.
I would also say it’s not a small difference that Vertex isn’t going to have eGFR-decline data or outcomes data for about 2 years. They’re going to get accelerated approval, while Otsuka and Vera get full approval based on actual kidney-function outcomes. Vertex is going to be marketing proteinuria, which can be a great marker, but there’s a big difference between kidney outcomes and a biomarker.
3. Revolution’s Explosive Launch
Moving on, one of the biggest stories in the sector over the last year or 2 has been Revolution Medicines and its drug, which is approved and launched for pancreatic adenocarcinoma. Adam, you’ve been following this closely, and I know that with any new launch there’s a bull-bear debate about what the initial sales numbers will look like. Give us the setup going into the first numbers from this launch.
Right. We’re getting the first indication of Q3 sales for what would amount to about 5 weeks of sales, given the late-August approval. There was a lot of speculation and a lot of expectations. Obviously, this drug is providing great benefit to pancreatic cancer patients, and there’s a lot of hype and excitement about it. What was that first print going to look like? Buy-side whisper numbers were in the $80 million to $100 million range.
And they blew that out of the water, right? I mean, $198 million in 5 weeks. Again, they blew the doors off pretty much every expectation. It was a phenomenal start to this launch, which looks like it might be one of the strongest oncology drug launches of all time.
Yeah. It was very shocking, and obviously there’s a big debate about valuation. This is a very big market cap for a single drug launch. But the data has been really great, and by all estimates, this was way above expectations.
One of the favorite hedge fund sayings is “short the launch.” Expectations always get ahead of themselves. What are your thoughts on the stock’s action in the aftermath? Anyone have any color?
Is the fear that this is going to flatten out in 3 quarters, and then what do you do until you get the label expansion into frontline or other indications? I don’t cover RevMed, but I’ve heard the bear case: it’s already expensive, it would be a huge takeout, and Yaron and I have talked about this in other calls.
Look at how Alumis and Insmed played out, where the buy side got to the numbers ahead of the sell side. People say consensus is low, but eventually the beats aren’t enough. Again, this isn’t a call on RevMed’s stock. It could still be a total monster, but I think that’s the historical comparison the bears are worried about.
Yeah, I hear the same thing, Paul. And again, Brian, you cut out, so I didn’t hear everything you said after I had spoken. But there was a certain amount of tailwind in that first 5 weeks because they had so many patients on the EAP and a lot of pent-up demand, which they won’t have in Q4 and moving forward.
The thing I hear most is that this is just a very expensive company now, a very expensive stock. So execution has to be perfect.
4. Drug Safety Controversies
All right, next up, Adam and I have both been following the story of a drug called Vykat XR since it was developed by a little company called Soleno Therapeutics. Adam, you’ve been writing prolifically about it since those early days, so I’m going to let you once again set this one up.
I think the debate here is pretty simple. This is a drug for Prader-Willi syndrome, which is a terrible disease. Patients have an insatiable obsession and desire to eat. They overeat, they’re obese, and they suffer from all the conditions that come with that.
Since this drug was approved about a year and a half ago, there have now been 8 deaths of patients who have been prescribed Vykat. Well over 100 patients have been hospitalized. This is all coming from the FDA’s AEMS safety database, which used to be called FAERS. I FOIA’d the death reports for my last story.
The case reports on the 7 deaths are pretty horrible. These are patients’ deaths, mainly involving hypoglycemia or some form of edema or swelling that contributed to the deaths. The issue, or the controversy, is that these are known comorbidities of Prader-Willi syndrome, particularly edema and swelling. They’re also known risks of Vykat; the label has safety warnings that the drug causes swelling.
How much is attributable to the drug, and how much to the comorbidities of the disease? What impact will all of this have on the drug’s uptake?
Yeah, I think both Paul and I cover Neurocrine, which purchased Soleno and now markets Vykat. I certainly covered Soleno, and I don’t know that I disagree with you about the risk here. Is causality going to be established, or has it been established?
The other side of the coin is that the data Vykat was approved on wasn’t traditional, knock-it-out-of-the-park, home-run data. It was approved on a randomized withdrawal study after the primary analysis wasn’t successful.
We see this a lot in different diseases, and I think we’re going to talk about something related to this in a few minutes. We wind up in a very gray area: drugs hurt people. Any powerful drug is going to cause some safety issue at some rate, sometimes even death. Even very safe drugs do that every now and then.
When we get into this gray area, where we think there’s efficacy but not to the extent we might see with a true appetite and obesity drug, it becomes a big debate in the orphan sector. It’ll be interesting to see how this plays out. This is obviously a really terrible disease, one of the worst I’ve ever come across, but I hear the issues here.
The question is whether they can maintain sales at all. This has negatively impacted Neurocrine as a stock so many times. It’s overshot even the price they paid for Soleno. At this point, generating any sort of cash flow from the deal might be a positive for the stock. The question is whether this is going to get—
The company is talking to the FDA. There seems to be some consideration for label changes or potentially a REMS, or something that would help mitigate some of these risks.
Adam, did you listen to their call?
I did.
Because I thought the Neurocrine CMO was super credible, and I thought she made a comment that they felt the label appropriately depicts the risk. You can say it’s the company saying that, but I felt like I heard that as: they don’t think the label’s going to change, but they are going to do this study in a high-risk population to look at that.
I think that’s a little bit of talking out of both sides. They say the label is fine, but they’re doing this study. I don’t think they would be doing the study if everything were fine.
Or if the FDA didn’t want it.
I think they’re looking at this because you might be able to tease out a population of patients where this risk is much higher. Not to cross diseases, but if you think about Duchenne, ambulatory and non-ambulatory patients are a little different. With Elevidys, they ultimately took it off the market for non-ambulatory patients.
Is there a patient characteristic or risk factor that might make this drug unsuitable for some patients versus others?
Makes sense.
Okay. And to keep it in the controversy, Madrigal reported this week, but the print may have been a little overshadowed by a whistleblower lawsuit. What’s the background here?
This one kind of came out of nowhere. The whistleblower lawsuit was actually filed back in early October, but it didn’t really get out there until Madrigal filed its 10-Q and disclosed the lawsuit.
A former executive of the company is claiming that drug-induced liver injuries and drug toxicity are tied to resmetirom. It was part of his job to look at pharmacovigilance. He identified these concerns in both the clinical trials and the postmarketing safety database, brought them to the attention of top management at Madrigal, and they basically told him to stop looking at the data. Then they demoted him, and he says he was forced to resign.
These are all allegations in the lawsuit, so it’s hard to know what to make of it. Is this a guy looking to get paid by the company? Are his claims legitimate? Obviously, the company is at a disadvantage because it hasn’t formally responded to the lawsuit yet.
And we’ve gotten statements from them saying they’re obviously going to defend themselves vigorously. I guess I don’t know how you guys feel about it. I’m curious: is this just an overhang on Madrigal for a little while until it gets cleared up?
I’m not too close to it. I don’t know, Paul. You’re on.
I’m not too close to it either, but what could be the ultimate consequences of this?
Well, I think that’s a good point. I think the point about drugs on the market—
The point the company makes—and it’s a good point—is that this drug has been approved for about 4 years. It’s now been prescribed to about 56,000 patients with MASH who have used Rezdiffra, and there’s no indication that the drug is tied to drug-induced liver injury. They just haven’t seen that. If this were an issue, if this were a problem, it would have surfaced already, and it hasn’t. That’s a persuasive argument.
I do wonder, how come we haven’t heard about this before? I was talking to some investors about this after the lawsuit came out, including one who’s a pretty significant shareholder. Their point was that we do doctor calls all the time, particularly with competition coming, and we talk to treating physicians in MASH. None of these physicians, who treat tons and tons of patients, have ever mentioned liver toxicity issues to the extent this guy is alleging. That’s very odd to them.
Yeah. Go ahead.
I was just going to say, in a world where it usually takes a lot to have a real, tangible impact on a drug that’s on the market, it’s hard to see what the path is here. We talk about situations where a drug on the market doesn’t work in its confirmatory trial, and it’s still complicated to know whether it’s going to get pulled. Or look at the Vykat XR situation, where there are patient deaths and we’re debating whether there are implications. In the context of this drug being so widely used, it’s harder to see how this meaningfully changes things. At least for me, it’s hard to see the path.
I think you mentioned it with FCS, too. You wind up in this dynamic when a drug is approved: how do you really establish causality? Part of the problem with MASH is that you’re talking about a progressive liver disease, so you can’t evaluate for DILI the way you traditionally can for a nonprogressive liver disease. These patients are generally going to continue progressing. Madrigal’s data looks good, so hopefully it’s improving more patients than are getting worse, but you’re still going to have patients progressing to F4 cirrhosis and liver transplant in the experience. How do you attribute that to the disease versus the drug?
I know, having massive scars from covering Intercept, that was always kind of the issue when you had control data, too. Here, you’re in a situation where you don’t really have control. It’s probably not liver toxic, given the number of patients who’ve had it, but disproving a negative in the commercial setting is very hard. Maybe moving on. Paul, I think you have a couple of things this week worth discussing. Let’s start with mushrooms.
Yeah. Please. Let’s start with mushrooms. Let’s finish with mushrooms. This is a really crazy situation. I don’t know how closely everyone here has been following it, but we’ve talked about Compass Pathways and psychedelics on this show. Compass is close to completing its NDA submission, has a Commissioner’s voucher, and may be able to get approval in the next handful of months for COMP360.
There’s been a nonprofit called the Usona Institute that’s also developing synthetic psilocybin for depression. They’ve done major depressive disorder; Compass has done treatment-resistant depression. The main difference is the severity of the population, but it’s a similar concept. Usona is very stealthy, from my perspective. They’ve completed Phase 2 and Phase 3. The Phase 3 trial completed a year ago, but the data isn’t public. Compass has said they’ve talked to the study’s PIs, who don’t know the data, which I think is a little atypical.
The perception was that this could come to market at some point. Usona has an admirable mission of trying to make this broadly available, or available to people who otherwise wouldn’t be able to get a psychedelic because of cost or access. No disparagement of the mission whatsoever. We just didn’t really know what the data was, and we still don’t know if the study was technically positive. I think the general view in psychedelics is that you’d need a second Phase 3 for approval.
It was a big surprise this week when a seemingly credible psychedelics reporter, someone who writes thoughtfully about the space, reported that Usona had completed an NDA filing for its product. Again, that’s super surprising because they have less data than Compass, and we haven’t seen the Phase 3 data. This creates a whole host of questions for Compass in the psychedelic space. The biggest question is what the commercial implications are for Compass if a nonprofit gets psilocybin approved at the same time, or maybe even first, and sets the price really low. Does that essentially undermine the Compass business model?
The other fact I should mention is that the head of CDER used to work at the Usona Institute, not that long ago. I’m not trying to imply anything, because we don’t know if this person has recused himself or whether any of this has anything to do with it. But it’s quite a coincidence, if it’s just a coincidence, that they’re filing under what seems like an expedited path against the backdrop of that FDA connection. It leaves all these open questions.
We spent time talking to the Compass team, and one interesting thing about all these psychedelics—and this has historically been a bear case for the space, but it might conversely be the reason Compass can preserve a real commercial model—is that the supply chain and use of these products are complicated. You need a REMS, a specialty pharmacy, and monitoring at these clinics. Monitoring costs money and effort, so the clinics need to be able to make money off these products in order to use them.
You could see a situation where Usona’s product is in certain channels and not others, maybe with the VA or something like that, while Compass, because its indication is treatment-resistant depression, continues to have this specialty model at interventional sites. This really threw investors a curveball this week. Is anyone else following this or have other thoughts?
Not that closely. It’s been interesting to watch the psychedelic space move both alongside advances in regulation and advances in decriminalization. I always wonder whether there’s a meeting point where high-priced drugs are just freely available. We have examples in epilepsy where cannabidiol is used and works very well, but a lot of the initial or anecdotal evidence is just from using CBD.
I don’t know where everyone else lives, but there are gummies on every street corner. You see the same thing with ketamine clinics, while Johnson & Johnson does very well selling esketamine. You see the push for psilocybin approvals, but mushrooms seem almost as freely available in corner smoke shops as THC at this point. I find the whole thing fascinating, because these drugs do work for people in many respects, but we’re also steadily moving toward a much freer decriminalization process.
I think the CBD analogy is a good one. When push comes to shove, with a serious disease, people tend to want a product they can rely on, knowing exactly what it is and that it’s given by a health care professional. In epilepsy, there are drug-drug interactions, and I feel like there will be a brand market in controlled settings regardless of whether people are eating mushroom chocolates for fun.
These launches are a little bit of a “show me” story. It’s a complicated model to execute. For Compass, the implications of the Usona situation are much closer to home. Investors can say, “Could payers just say, ‘Try the cheaper one first’?” I think this is a complicated market. If these were small molecules that were unscheduled, that would be a very, very big risk.
For the other psychedelics that have different mechanisms or modalities, like LSD or 5-MeO-DMT, this seems like it would probably have little impact.
Yeah, for sure. I don’t want to bring down everyone’s trip going into the weekend, but there’s another story this week that’s maybe a little bit similar to the Vicat story in gene therapy. Zolgensma has had a tough run of it, but it’s been one of the shining stars in gene therapy. So, Paul, I’ll kick it back to you. What did we learn this week about Zolgensma? What are your takeaways?
I’ll be brief, because we have a few other topics. Essentially, a few different media outlets reported a handful of tumor cases in the postmarketing setting among patients who received Zolgensma. I don’t know the veracity of these different posts or reports, but a parent of a patient had talked about how Zolgensma had been linked to tumors and Novartis hadn’t provided all the information, or things like that. Again, I don’t know how real that is, but multiple articles covered the topic.
One notable detail reported here is that a couple of the tumor cases showed evidence of vector integration. That has always been the theoretical risk with AAV: DNA damage, carcinogenicity, or things like that. In the context of SMA, especially types 1 and 2, the disease is so severe that it’s hard to believe a therapy like Zolgensma has significantly changed the risk-benefit profile. At least, I’d say the risk-benefit still looks favorable. I’m not saying the risk hasn’t changed, but there are other treatments. Spinraza is still such an unbelievable drug. The fact that it’s given intrathecally and has remained resilient alongside a one-time gene therapy and an oral medication really tells you what patients and physicians think about it.
For the rest of the gene therapy space, I’ve always had a hard time getting excited about a program for a disease that has other good therapeutic alternatives or doesn’t carry significant morbidity or mortality. We’ve seen other safety issues emerge postmarketing, like liver injury and other issues that can cause death. To me, this reaffirms that AAV currently feels like a rare disease modality. More broadly, developing elsewhere is at your own peril.
Yeah, that’s a good rundown. We have a couple of data previews and data lookbacks. I’m going to pass it over to Yaron. I’d love to hear your takeaways from the key ASH abstracts released this week, as well as your thoughts on the Novartis data from its failed Lp(a) program and what that means for the space.
Maybe just to pause on the last point: there are actually 2 recent approvals from Ultragenyx. One is for GSD1a, a disease that requires cornstarch throughout the day because patients can otherwise crash from hypoglycemia. That’s called Glycosade, and it’s just launching. The other is for MPS IIIA, a fairly serious neurodevelopmental disorder with significant unmet need. That’s called UX111. You’d think that one will launch well, and then they’ll be filing for OTC deficiency soon. Of course, there are drugs for that, too. There are going to be 3 more AAV8s and AAV9s coming to market, so we’ll continue to follow that.
Let’s do rapid fire. We’ll start with Lp(a). The AHA presentation is tomorrow morning at 8:45 a.m., so if you’re running or walking the dog, you can tune in. We know the drug is pelacarsen, from Ionis and Novartis, and that program has now failed, so it’s very unlikely to go anywhere else. What we’ll all be looking for is whether there were any subsets that might be more amenable to therapy. It looks like the drug really didn’t have any material benefit at all. These are patients who, as we’ve discussed before, were very well controlled on LDL and on other risk factors, including hypertension.
Companies in the space like Amgen, Lilly, and AstraZeneca, which are conducting major studies, will be looking for subsets that might benefit from therapy, or whether this really needs to be developed as primary prevention. Amgen has said that, based on these data, there are a couple of things they might change in their studies, but that’s still very much to be determined. Recall that the original data suggested—and we’ve covered this—that Lp(a) should be a modifiable genetic risk driver of disease. As more data have emerged, though, the more recent evidence suggests it’s probably much less of a driver when patients are otherwise very well controlled. That’s what we’ll be looking for tomorrow: whether there’s any correlation between underlying LDL levels and risk, versus Lp(a).
While we’re still on Amgen, its Sjögren’s data are coming next Wednesday at 8:45 a.m. at ACR. That’s the late breaker for dazodalibep in systemic disease. The data were really strong, much better than the ianalumab data, which are in front of the agency through Novartis and could potentially get approval by the end of this year. The ianalumab data had 2 Phase 3 studies that needed to be pulled together to hit statistical significance in systemic disease. Dazodalibep hit it out of the ballpark in Phase 3, mirroring Phase 2, and importantly showed benefit on symptoms as well.
The 24-week data hit both the primary and secondary endpoints. The 12-week data hit the primary endpoint, I think, and showed trends on symptoms only. The next study, coming by the end of the year, is in patients with symptomatic disease, which is about two-thirds to 75% of patients. That’s a big deal, and we’ll all be looking at the ACR data for a hint about those upcoming results, which we’re fairly optimistic about.
Amgen also continues to beat numbers. It has a lot of pipeline activity and a lot coming next year. It enrolled all of its MariTide studies really quickly and has now launched a pen formulation in a clinical study, with data expected by June of next year. Assuming success, it will probably file in the second half of next year with the pen, and it’s already doing switching studies from other GLP-1s. Lots going on with Amgen; it was a beat and raise.
BeOne also reported another huge beat and raise yesterday for Brukinsa, the leading CLL drug. Most importantly, BeOne has a BTK degrader and will be first in class. It has now spoken with the FDA and said the Phase 2 was positive. Because it’s first in class, the company will be doing more follow-up to assess durability. It specifically said this isn’t safety-related. We think the filing, which was hoped for late this year, is now moving to the middle of next year. We believe the FDA wants to see a minimum amount of follow-up across all patients and patient subsets, not just a median amount of follow-up.
That probably has to do with the plan to include patients who failed Jaypirca, Lilly’s latest approved BTK inhibitor. BeOne is doing a Phase 3 head-to-head study against that drug, and it’s going very well. They absolutely believe, and we agree, that they’ll be able to show superiority head-to-head. But because they want a label in the refractory setting for patients who failed Lilly’s drug, the FDA probably said those patients are newer in the study, so it wants more follow-up. That’s pushed the filing to the middle of next year, but BeOne is affirming that it could file. A lot is going on with BeOne.
We’ve already covered the Revolution Medicines collaboration and its impact on Tango. On their call yesterday, they reiterated that they don’t expect a drug-drug interaction between RMC-6236, the Revolution Medicines drug, and their own PRMT5 inhibitor. Recall that Tango does have a drug-drug interaction, and that’s why we believe Revolution Medicines ultimately did the formal collaboration with BeOne for that.
Finally, I know we’re doing rapid fire, but the ASH abstracts came out, and what’s really interesting is how tough this could be for Legend and the impact it may face from Gilead’s anito-cel. The anito-cel abstract came out. Remember, they’re in front of the FDA, and the PDUFA date is December 23rd.
Anito-cel doesn’t have the same toxicity that Legend has. We’re all waiting to hear the efficacy, so the abstract really didn’t have a lot of new efficacy data from Gilead. We’ll probably get that updated at ASH. I think it’s expected that the Gilead product won’t be quite as effective, but will be a lot safer.
What was new from Legend is that they’re showing they can do prophylaxis by giving a lot of steroids and, as a result, reduce the parkinsonism risk from 4%–6% to 1.25%. There’s still a risk, but the other updated element was a little more data for their in vivo CAR-T for lymphoma, with updated data from EHA midyear. Now, essentially everyone has a 100% response rate, and responses are fairly durable, up to 5 months. The data so far look very interesting. In terms of safety, it’s fairly clean, with much higher response rates so far than ex vivo CAR-T, like Breyanzi from Bristol or Yescarta from Gilead. So in vivo CAR-T looks fairly promising. There’s a lot to look forward to at ASH.
Yeah, I think the most interesting thing about the ASH abstract was that, after all these years, it was just a one-minute takeaway at the end of this discussion—how little there wound up being from ASH abstracts this year, and how busy we were talking about other stuff. Well, with that, we’re out of time. This was great.